|
US4399216A
(en)
|
1980-02-25 |
1983-08-16 |
The Trustees Of Columbia University |
Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
|
|
US4713339A
(en)
|
1983-01-19 |
1987-12-15 |
Genentech, Inc. |
Polycistronic expression vector construction
|
|
AU2353384A
(en)
|
1983-01-19 |
1984-07-26 |
Genentech Inc. |
Amplification in eukaryotic host cells
|
|
US4970300A
(en)
|
1985-02-01 |
1990-11-13 |
New York University |
Modified factor VIII
|
|
AU6029594A
(en)
|
1993-01-15 |
1994-08-15 |
Enzon, Inc. |
Factor viii - polymeric conjugates
|
|
JPH11501506A
(ja)
|
1994-12-12 |
1999-02-09 |
ベス イスラエル デアコネス メディカル センター |
キメラ型サイトカインおよびその利用
|
|
WO1997003193A1
(en)
|
1995-07-11 |
1997-01-30 |
Chiron Corporation |
Novel factor viii:c polypeptide analogs with altered metal-binding properties
|
|
SE9503380D0
(sv)
|
1995-09-29 |
1995-09-29 |
Pharmacia Ab |
Protein derivatives
|
|
US20040092442A1
(en)
|
1996-04-24 |
2004-05-13 |
University Of Michigan |
Inactivation resistant factor VIII
|
|
WO1997040145A1
(en)
|
1996-04-24 |
1997-10-30 |
The Regents Of The University Of Michigan |
Inactivation resistant factor viii
|
|
ATE283034T1
(de)
|
1998-04-27 |
2004-12-15 |
Opperbas Holding Bv |
Pharmazeutische zusammensetzungen enthaltend faktor viii und neutrale liposomen
|
|
US6660843B1
(en)
|
1998-10-23 |
2003-12-09 |
Amgen Inc. |
Modified peptides as therapeutic agents
|
|
US6887470B1
(en)
|
1999-09-10 |
2005-05-03 |
Conjuchem, Inc. |
Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
|
|
WO2002060951A2
(en)
|
2001-01-12 |
2002-08-08 |
The American National Red Cross |
Methods and compositions for reducing heparan sulfate proteoglycan-mediated clearance of factor viii
|
|
EP2110385A1
(en)
|
2001-06-14 |
2009-10-21 |
The Scripps Research Institute |
Stabilized factor VIII with engineered disulfide bonds
|
|
AU2003210806A1
(en)
|
2002-03-05 |
2003-09-22 |
Eli Lilly And Company |
Heterologous g-csf fusion proteins
|
|
DE60332011D1
(de)
|
2002-04-29 |
2010-05-20 |
Sanquin Bloedvoorziening |
Antagonisten der interaktion zwischen faktor viii und lrp ("low-density lipoprotein receptor related protein")
|
|
US7041635B2
(en)
|
2003-01-28 |
2006-05-09 |
In2Gen Co., Ltd. |
Factor VIII polypeptide
|
|
SI1596887T1
(sl)
|
2003-02-26 |
2022-05-31 |
Nektar Therapeutics |
Konjugati polimer-del faktorja VIII
|
|
EP3002012A1
(en)
|
2003-05-06 |
2016-04-06 |
Biogen Hemophilia Inc. |
Clotting factor-fc chimeric proteins to treat hemophilia
|
|
TWI353991B
(en)
|
2003-05-06 |
2011-12-11 |
Syntonix Pharmaceuticals Inc |
Immunoglobulin chimeric monomer-dimer hybrids
|
|
MXPA05013565A
(es)
|
2003-06-12 |
2006-03-09 |
Lilly Co Eli |
Proteinas de fusion analogas al glp-1.
|
|
CA2551916C
(en)
|
2003-12-31 |
2014-04-29 |
Merck Patent Gesellschaft Mit Beschraenkter Haftung |
Fc-erythropoietin fusion protein with improved pharmacokinetics
|
|
US7670595B2
(en)
|
2004-06-28 |
2010-03-02 |
Merck Patent Gmbh |
Fc-interferon-beta fusion proteins
|
|
PT2371856T
(pt)
|
2004-11-12 |
2022-08-12 |
Bayer Healthcare Llc |
Modificação de fviii direcionada a sítio
|
|
CA2591852A1
(en)
|
2004-12-27 |
2006-07-06 |
Baxter International Inc. |
Polymer-von willebrand factor-conjugates
|
|
EP1874815A1
(en)
|
2005-04-14 |
2008-01-09 |
CSL Behring GmbH |
Modified coagulation factor viii with enhanced stability and its derivates
|
|
EP1816201A1
(en)
|
2006-02-06 |
2007-08-08 |
CSL Behring GmbH |
Modified coagulation factor VIIa with extended half-life
|
|
EP2010222A1
(en)
|
2006-03-31 |
2009-01-07 |
Baxter International Inc. |
Pegylated factor viii
|
|
EP3896090B1
(en)
|
2006-06-14 |
2022-01-12 |
CSL Behring GmbH |
Proteolytically cleavable fusion protein comprising a blood coagulation factor
|
|
AU2007338298B2
(en)
|
2006-12-22 |
2013-02-07 |
Csl Behring Gmbh |
Modified coagulation factors with prolonged in vivo half-life
|
|
AU2009262476C1
(en)
|
2008-06-24 |
2016-06-02 |
Csl Behring Gmbh |
Factor VIII, von Willebrand factor or complexes thereof with prolonged in vivo half-life
|
|
PT2499165T
(pt)
*
|
2009-11-13 |
2016-10-28 |
Grifols Therapeutics Inc |
Preparações que contêm o fator de von willebrand (vwf), e métodos, kits e utilizações relacionadas com as mesmas
|
|
WO2013093760A2
(en)
|
2011-12-19 |
2013-06-27 |
Grifols, S.A. |
Compositions, methods, and kits for preparing sialylated recombinant proteins
|
|
CN104271150A
(zh)
|
2012-01-12 |
2015-01-07 |
比奥根艾迪克Ma公司 |
嵌合因子viii多肽及其用途
|
|
DK2814502T3
(en)
|
2012-02-15 |
2017-12-18 |
Csl Behring Gmbh |
Von Willebrand Factor variants with improved Factor VIII binding affinity
|
|
WO2013083858A1
(en)
|
2012-04-24 |
2013-06-13 |
Novo Nordisk A/S |
Compounds suitable for treatment of haemophilia
|
|
NZ703366A
(en)
|
2012-07-11 |
2018-03-23 |
Amunix Operating Inc |
Factor viii complex with xten and von willebrand factor protein, and uses thereof
|
|
ES2657291T3
(es)
*
|
2013-04-22 |
2018-03-02 |
Csl Ltd. |
Un complejo covalente de factor de von Willebrand y factor VIII asociado por un puente disulfuro
|
|
JP2016522219A
(ja)
|
2013-06-12 |
2016-07-28 |
ノヴォ ノルディスク アー／エス |
血友病の治療に適する化合物
|
|
KR20230007555A
(ko)
*
|
2013-06-28 |
2023-01-12 |
바이오버라티브 테라퓨틱스 인크. |
Xten을 지닌 트롬빈 절단가능한 링커 및 이의 용도
|
|
CN106659771B
(zh)
|
2014-07-02 |
2021-09-24 |
康诺贝林伦瑙有限公司 |
修饰的von Willebrand因子
|
|
CN107787328B
(zh)
*
|
2015-05-22 |
2021-08-06 |
康诺贝林伦瑙有限公司 |
用于治疗血友病的截短的血管性血友病因子多肽
|
|
CN107810194B
(zh)
*
|
2015-05-22 |
2021-10-08 |
康诺贝林伦瑙有限公司 |
用于制备经修饰的血管性血友病因子的方法
|
|
RU2018128613A
(ru)
*
|
2016-01-07 |
2020-02-07 |
Цсл Беринг Ленгнау Аг |
Мутированный фактор фон виллебранда
|
|
RU2018128582A
(ru)
*
|
2016-01-07 |
2020-02-11 |
Цсл Беринг Ленгнау Аг |
Мутированный укороченный фактор фон виллебранда
|